SK Life Science presents real-world data on epilepsy drug at US neurology meet

SK Life Science, the U.S. subsidiary of SK biopharmaceuticals, is presenting six new studies on its epilepsy drug Xcopri (ingredient: cenobamate) at the 77th Annual Meeting of the American Academy of Neurology (AAN), taking place from April 5 to 9 in San Diego, California.

The research includes real-world data (RWD) and clinical outcomes demonstrating the potential of cenobamate to significantly reduce seizures and improve overall epilepsy management.

One of the key presentations highlights a retrospective, multi-center observational study in the U.S., involving 37 adult patients aged 18 and older with focal seizures. These patients had been treated with cenobamate at a minimum dose of 50 mg/day as adjunctive therapy for at least two weeks.

The study utilized data from responsive neurostimulation (RNS) devices to objectively assess treatment efficacy. Results showed a significant reduction in the frequency of epileptiform events during the 12-week treatment period compared to an 8-week baseline.

Notably, average event frequency dropped from 15.7 per 28 days at baseline to 2.5 per 29 days, representing an approximate 84 percent decrease.

The most commonly reported adverse events were dizziness and drowsiness. However, these were generally managed by titrating the cenobamate dose gradually or adjusting the dosage of concomitant anti-seizure medications (ASMs).

“SK Life Science is committed to setting a new standard in epilepsy care through research and education that brings real change to patients’ lives,” SK Life Science Vice President of Medical Affairs Louis Ferrari said. “Seizure freedom remains a critical goal for many patients, yet it is often difficult to achieve.”

This study is meaningful in that it used RNS data as an objective marker to evaluate the effects of cenobamate and other adjunctive ASMs, Ferrari added.

In addition to this study, SK Life Science is presenting a total of six poster abstracts at AAN 2025, covering the therapeutic efficacy, safety profile, and broader treatment potential of cenobamate across diverse patient populations. The company expects these findings to support future treatment strategies and highlight cenobamate’s expanding clinical utility.